Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

25.34
+0.86003.51%
Post-market: 25.980.6400+2.53%19:09 EDT
Volume:2.18M
Turnover:54.54M
Market Cap:3.18B
PE:-7.84
High:25.48
Open:24.45
Low:24.13
Close:24.48
52wk High:28.72
52wk Low:7.91
Shares:125.35M
Float Shares:88.65M
Volume Ratio:3.11
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2326
EPS(LYR):-3.2900
ROE:-69.95%
ROA:-23.11%
PB:6.06
PE(LYR):-7.70

Loading ...

Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating

MT Newswires Live
·
Dec 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-ProPetro, Nvidia, Citigroup

Reuters
·
Dec 12, 2025

Arcus Biosciences Shares Down 12% Premarket After Co and Gilead Scrap Late-Stage Trial of Cancer Drug Combo

THOMSON REUTERS
·
Dec 12, 2025

Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment

Dow Jones
·
Dec 12, 2025

BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio

Reuters
·
Dec 12, 2025

Arcus Biosciences Refocuses R&D on Casdatifan and Inflammation Programs, Plans New Clinical Trials and Data Readouts Through 2028

Reuters
·
Dec 12, 2025

Arcus Biosciences Inc: Star-221 and Phase 2 Edge-Gastric Studies Will Be Discontinued

THOMSON REUTERS
·
Dec 12, 2025

Arcus Biosciences Inc - Continues to Expand Casdatifan Program With Data Readouts in 2026

THOMSON REUTERS
·
Dec 12, 2025

Arcus Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

THOMSON REUTERS
·
Dec 12, 2025

Gilead Halts Phase 3 STAR-221 Trial After Domvanalimab Combo Fails to Improve Survival in Gastric Cancer

Reuters
·
Dec 12, 2025

Arcus Biosciences Grants New Employee Stock Options and Restricted Stock Units

Reuters
·
Dec 10, 2025

President Juan C. Jaen Reports Disposal of Arcus Biosciences Inc. Common Shares

Reuters
·
Dec 06, 2025

Arcus Biosciences Chief Accounting Officer Alexander Azoy Reports Disposal of Common Shares

Reuters
·
Dec 02, 2025

Arcus Biosciences Is Maintained at Neutral by B of A Securities

Dow Jones
·
Nov 29, 2025

Arcus Biosciences price target raised to $26 from $17 at BofA

TIPRANKS
·
Nov 28, 2025